• Bipolar Disorder
    • Eduardo Eduard
    • Eduardo Eduard: Influence Statistics

      Eduardo Eduard

      Eduardo Eduard

      Show email address

      Bipolar and Depressive Disorders Unit, Hospital Clinic (EJ, EV), University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. | Bipolar and Depressive Disorders ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Eduardo Eduard:Expert Impact

      Concepts for whichEduardo Eduardhas direct influence:Bipolar disorder,Bipolar patients,Bipolar disorders,Bipolar depression,Patients bipolar disorder,Cognitive impairment,Acute mania,Schizoaffective disorder.

      Eduardo Eduard:KOL impact

      Concepts related to the work of other authors for whichfor which Eduardo Eduard has influence:Bipolar disorder,Mental health,Depressive symptoms,Cognitive impairment,Major depression,Suicidal ideation,Patients schizophrenia.

      KOL Resume for Eduardo Eduard


      Bipolar and Depressive Disorders Unit, Hospital Clinic (EJ, EV), University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.

      Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Barcelona, Spain

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Eduardo Eduard is among the top experts in the world.
      Concept World rank
      obstetric complications pregnancy #1
      episodes mixed #1
      reliability adults #1
      mdd severe #1
      patients mixed episodes #1
      treatment manic #1
      guidelines bipolar #1
      phases bipolar #1
      smd differences #1
      clinical symptoms functioning #1
      background bipolar #1
      variance psychosocial functioning #1
      rs10997870 polymorphism #1
      intercontinental region #1
      hc fw decrease #1
      pregnancy period trimester #1
      subclinical depressive symptoms #1
      determinants psychosocial functioning #1
      alliance bipolar disorder #1
      antipsychotics bipolar #1
      patients european countries #1
      functioning adult #1
      patients depressive onset #1
      survey 70 #1
      bipolar acute episodes #1
      sd262 #1
      pntu #1
      treatment mania #1
      neurocognitive symptoms lockdown #1
      weightrd #1
      complaints bipolar #1
      app life #1
      cortiso #1
      drugs maintenance treatment #1
      fep metaanalysis #1
      adjunctive mood stabilizer #1
      z327 #1
      n20787 #1
      identify clinical #1
      manacor study #1
      biased accuracy #1
      functional impairment patients #1
      patients naturalistic treatment #1
      disorder evidence #1
      disorder cognitive #1
      symptoms order #1
      euthymic bipolar patients #1
      ltg bipolar patients #1
      psychiatric patients pma #1
      bipolar disorders #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Eduardo Eduard

      KOL-Index: 20721

      BACKGROUND: This study examined the efficacy and safety of quetiapine in combination with lithium or divalproex compared with placebo with lithium or divalproex in the prevention of recurrent mood events in bipolar I patients, most recent episode mania, depression, or mixed.

      METHODS: Patients received open-label quetiapine (400-800 mg/day; flexible, divided doses) with lithium or divalproex (target serum concentrations 0.5-1.2 mEq/L and 50-125 microg/mL, respectively) for up to 36 weeks ...

      Known for Quetiapine Placebo | Lithium Divalproex | Mood Event | Patients Bipolar Disorder | Time Recurrence
      KOL-Index: 17748

      OBJECTIVE: Since stability of DSM-IV diagnoses of disorders with psychotic features requires validation, we evaluated psychotic patients followed systematically in the McLean-Harvard International First Episode Project.

      METHOD: We diagnosed 517 patients hospitalized in a first psychotic illness by SCID-based criteria at baseline and at 24 months to assess stability of specific DSM-IV diagnoses.

      RESULTS: Among 500 patients (96.7%) completing the study, diagnoses remained stable in 77.6%, ...

      Known for Psychotic Disorder | Major Diagnosis | Episode Project | Harvard International | Diagnoses Schizophrenia
      KOL-Index: 17049

      The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, ...

      Known for Bipolar Disorder | Canadian Network | 2018 Guidelines | Lithium Quetiapine | Anxiety Treatments
      KOL-Index: 16518

      OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray.

      METHODS: This was a phase 3, double-blind, active-controlled, ...

      Known for Resistant Depression | Esketamine Nasal | Antidepressant Treatment | Efficacy Safety | Newly Initiated
      KOL-Index: 15848

      BACKGROUND: To evaluate the 12-week outcomes (effectiveness, tolerability, and patterns of medication use) of olanzapine (either in antimanic monotherapy or in combination with other antipsychotics, anticonvulsants, and/or lithium) in patients with bipolar mania or mixed mania.

      METHOD: EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication) is a 24-month prospective observational study of in- and outpatients with acute mania/mixed mania conducted in 14 European ...

      Known for Olanzapine Monotherapy | European Mania | Combination Therapy | Bipolar Longitudinal | Antimanic Agents
      KOL-Index: 15505

      OBJECTIVE: This study evaluated the long-term tolerability and effectiveness of aripiprazole adjunctive to lithium or valproate in partial responders with bipolar mania.

      METHODS: Completers of a 6-week double-blind comparison of adjunctive aripiprazole versus placebo in bipolar mania partially responsive to lithium or valproate monotherapy could enter a 46-week extension treatment with open-label adjunctive aripiprazole plus lithium (ARI + LI) or valproate (ARI + VAL). Safety, efficacy ...

      Known for Bipolar Mania | Aripiprazole Patients | Ari Val | Combination Female Humans | Adjunctive Lithium
      KOL-Index: 15184

      BACKGROUND: The detection and diagnosis of present or past hypomanic episodes is of key importance for the differential diagnosis between depressive disorders and type II bipolar disorder. However, there are few instruments available to satisfactorily screen for the latter condition. The Hypomania Symptom Checklist-32 (HCL-32) is a self-applied questionnaire with 32 hypomania items and 8 severity and functional impact items which is being developed in several European countries for this ...

      Known for Hypomania Symptom | Bipolar Disorder | Major Diagnosis | Psychometric Properties | Spanish Version
      KOL-Index: 15095

      TERMINOLOGY AND PRINCIPLES OF COMBINING ANTIPSYCHOTICS WITH A SECOND MEDICATION: The term "combination" includes virtually all the ways in which one medication may be added to another. The other commonly used terms are "augmentation" which implies an additive effect from adding a second medicine to that obtained from prescribing a first, an "add on" which implies adding on to existing, possibly effective treatment which, for one reason or another, cannot or should not be stopped. The ...

      Known for Combination Treatment | Augmentation Antipsychotics | Antipsychotic Monotherapy | Severe Mental Illness | Lithium Valproate
      KOL-Index: 15095

      The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence and is designed to be used in conjunction with the previous publications. The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate, and several atypical antipsychotics continue to be ...

      Known for Bipolar Disorder | Canadian Network | Canmat Guidelines | Collaborative Update | Acute Mania
      KOL-Index: 14745

      OBJECTIVE: The authors evaluated the efficacy, safety, and tolerability of cariprazine, an atypical antipsychotic candidate, in adult patients with acute bipolar I depression.

      METHOD: This was an 8-week multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with bipolar I disorder experiencing a current major depressive episode. Patients were randomly assigned (1:1:1:1) to receive placebo or cariprazine at 0.75, 1.5, ...

      Known for Cariprazine Placebo | 30 Day | Efficacy Safety | Baseline Week | Patients Bipolar
      KOL-Index: 14541

      OBJECTIVE: The authors evaluated the efficacy and safety of quetiapine plus lithium or divalproex in the prevention of recurrent mood events in patients with stabilized bipolar I disorder.

      METHOD: A total of 1,953 patients received open-label quetiapine (400-800 mg/day in flexible, divided doses) with either lithium or divalproex (target serum concentrations 0.5-1.2 meq/liter and 50-125 microg/ml, respectively) for up to 36 weeks. After at least 12 weeks of clinical stability, 628 ...

      Known for Quetiapine Lithium | Maintenance Treatment | Mood Event | Time Recurrence | Patients Bipolar Disorder

      Bipolar disorders

      KOL-Index: 14369

      Bipolar disorders are a complex group of severe and chronic disorders that includes bipolar I disorder, defined by the presence of a syndromal, manic episode, and bipolar II disorder, defined by the presence of a syndromal, hypomanic episode and a major depressive episode. Bipolar disorders substantially reduce psychosocial functioning and are associated with a loss of approximately 10-20 potential years of life. The mortality gap between populations with bipolar disorders and the ...

      Known for Bipolar Disorders | Childhood Maltreatment | Depressive Disorder | Cardiovascular Disease | Psychosocial Functioning
      KOL-Index: 14095

      OBJECTIVE: Many studies have reported that cognitive ability may be predictive of the functional outcome for patients with schizophrenia. However, no study has prospectively examined these aspects in schizophrenia and bipolar disorders simultaneously. The present study attempted to analyze if neurocognition and clinical status predicts the real-life functioning for patients with schizophrenia or bipolar I disorder, using a longitudinal design.

      METHOD: Forty-seven schizophrenic and 43 ...

      Known for Functional Outcome | Patients Schizophrenia | Year Follow | Clinical Predictors | Bipolar Disorders
      KOL-Index: 14044

      DIAGNOSIS AND EPIDEMIOLOGY: DSM-IV, specifically its text revision DSM-IV-TR, remains the preferred diagnostic system. When employed in general population samples, prevalence estimates of bipolar disorder are relatively consistent across studies in Europe and USA. In community studies, first onset of bipolar mood disorder is usually in the mid-teenage years and twenties, and the occurrence of a major depressive episode or hypomania is usually its first manifestation. Since reliable ...

      Known for Bipolar Depression | Consensus Meeting | Children Adolescents | Mania Hypomania | Disorder Clinical

      Key People For Bipolar Disorder

      Top KOLs in the world
      Eduardo Eduard
      bipolar disorder cognitive impairment acute mania
      Robert M Post
      bipolar disorder affective illness depressed patients
      Susan L McElroy
      bipolar disorder binge eating bulimia nervosa
      Paul E Keck
      bipolar disorder acute mania united states
      Joseph R Calabrese
      bipolar disorder suicidal ideation rapid cycling
      Gary S Sachs
      bipolar disorder rapid cycling acute mania

      Bipolar and Depressive Disorders Unit, Hospital Clinic (EJ, EV), University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. | Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, Universi

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.